Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi to hand over five consumer healthcare products to Ipsen

Sanofi to hand over five consumer healthcare products to Ipsen

15th February 2017

Sanofi will be selling the European rights of five products from its consumer healthcare portfolio to fellow pharmaceutical firm Ipsen in a deal worth 83 million euros (70 million pounds).

Following the closure of the deal, Ipsen will have ownership of the pain management drug Prontalgine, which is currently exclusive to France, as well as the laxative Suppositoria Glycerini and cough and flu medicines Mucothiol and Mucodyne.

The fifth drug that Ipsen will acquire from Sanofi will be the antispasmodic Buscopan, meaning its consumer healthcare portfolio will grow significantly.

For Sanofi, the deal will mean that it is fulfilling the terms of the consumer healthcare asset swap it had set up with Boehringer Ingelheim.

Commenting on the deal, Jean Fabre, executive vice-president of primary care at Ipsen, stated: "The key asset Prontalgine, a well-established and growing market player for pain management in france with mid-30 percent market share, will help us achieve a critical mass at the pharmacy level."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: DragonImages via iStockADNFCR-8000103-ID-801832408-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.